Telmisartan Restricts Chikungunya Virus Infection In Vitro and In Vivo through the AT1/PPAR-γ/MAPKs Pathways-Reference-Cited by-同舟云学术

Telmisartan Restricts Chikungunya Virus Infection In Vitro and In Vivo through the AT1/PPAR-γ/MAPKs Pathways

Published:2022-01-18 Issue:1 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

De Saikat¹²^ORCID,Mamidi Prabhudutta¹,Ghosh Soumyajit¹²,Keshry Supriya Suman¹³,Mahish Chandan⁴,Pani Sweta Smita¹,Laha Eshna¹²,Ray Amrita¹²,Datey Ankita¹³,Chatterjee Sanchari¹²,Singh Sharad¹³,Mukherjee Tathagata⁴,Khamaru Somlata⁴,Chattopadhyay Subhasis⁴,Subudhi Bharat Bhusan⁵,Chattopadhyay Soma¹^ORCID

Affiliation:

1. Institute of Life Sciences, Bhubaneswar, India

2. Regional Centre for Biotechnology, Faridabad, India

3. School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT) University, Bhubaneswar, India

4. School of Biological Sciences, National Institute of Science Education and Research, HBNI, Bhubaneswar, India

5. School of Pharmaceutical Sciences, Siksha O Anusandhan Deemed to be University, Bhubaneswar, India

Abstract

Chikungunya virus (CHIKV) has reemerged as a global public health threat. The inflammatory pathways of the renin-angiotensin system (RAS) and peroxisome proliferator-activated receptor-gamma (PPAR-γ) are usually involved in viral infections.

Funder

Council of Scientific and Industrial Research, India

Department of Biotechnology, Ministry of Science and Technology, India

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01489-21

Reference50 articles.

1. Risks to the Americas associated with the continued expansion of chikungunya virus

2. Chikungunya, a paradigm of neglected tropical disease that emerged to be a new health global risk